Originally identified as an anti-tumor drug, aclacinomycin A is the first described non-peptidic inhibitor showing discrete specificity for the chymotrypsin-like activity of the 20S proteasome. Aclacinomycin A has no effect on cathepsin B, it stimulates trypsin activity but inhibits the activity of both chymotrypsin and calpain.
Product Details
| Alternative Name: | Aclarubicin |
| |
| Formula: | C42H53NO15 |
| |
| MW: | 811.9 |
| |
| CAS: | 57576-44-0 |
| |
| Purity: | ≥95% (TLC) |
| |
| Appearance: | Yellow powder with orange cast. |
| |
| Solubility: | Soluble in DMSO (25mg/ml) or dimethyl formamide (25mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Activin A downregulates the CD69-MT2A axis via p38MAPK to induce erythroid differentiation that sensitizes BCR-ABL-positive cells to imatinib: C.W. Chen, et al.; Exp. Cell Res.
417, 113219 (2022),
Abstract;
Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test: M. Lehmann, et al.; Environ. Mol. Mutagen.
43, 250 (2004),
Abstract;
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation: K. Saito, et al.; Int. J. Hematol.
71, 238 (2000),
Abstract;
The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome: M. E. Figueiroda-Pereira et al.; J. Biol. Chem.
271, 16455 (1996),
Abstract;
Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin: T. Isoe et al.; Biochim. Biophys. Acta.
1117, 131 (1992),
Abstract;
